Growth hormone secretagogues (GHS) are a class of compounds studied for their ability to stimulate the release of growth hormone from the pituitary gland, working through mechanisms distinct from growth hormone itself. This overview summarises the main research subclasses and the pathways they engage.
Two Main Mechanistic Families
Research-grade growth hormone secretagogues generally fall into two mechanistic families: growth hormone releasing hormone (GHRH) analogues, such as Sermorelin, Tesamorelin and CJC-1295, which act on the GHRH receptor; and ghrelin-receptor agonists (sometimes called growth hormone releasing peptides, or GHRPs), such as Ipamorelin, GHRP-2, GHRP-6 and Hexarelin, which act on the ghrelin/growth hormone secretagogue receptor.
GHRH Analogue Research
GHRH analogues are studied for their ability to mimic the body’s natural growth-hormone-releasing hormone, engaging the same receptor pathway and, in preclinical models, producing a pulsatile pattern of growth hormone release similar to endogenous signalling. Tesamorelin in particular has an unusually well-developed clinical research record among this class, which has made it a frequently referenced compound in comparative GHS literature.
Ghrelin-Receptor Agonist Research
GHRPs act on a distinct receptor from GHRH analogues, and are often studied in combination with a GHRH analogue in research models, on the basis that the two mechanisms engage different points in the growth-hormone release pathway. Ipamorelin is frequently referenced in the literature for its receptor selectivity relative to earlier GHRPs, a property researchers have examined in relation to off-target signalling in secretagogue research models.
Downstream Research: IGF-1 and Body Composition
Because growth hormone’s downstream effects are substantially mediated by insulin-like growth factor 1 (IGF-1), GHS research frequently measures IGF-1 as a secondary endpoint alongside growth hormone pulsatility, and a portion of the preclinical literature examines body-composition-related outcomes in animal models following GHS administration.
Research Handling Considerations
Most GHS peptides are supplied as lyophilized powders and follow the general handling and storage practices described in our lyophilized-compound and storage-stability guides: cold-chain storage, protection from light and moisture, and prompt refrigerated use once reconstituted.
Scope of Current Research
The GHS literature ranges from basic receptor-pharmacology studies to animal models and, for a subset of compounds such as Tesamorelin, human clinical research. Researchers should evaluate the specific compound and endpoint relevant to their protocol against current primary literature.
Research Use Only. This overview is provided for general scientific education about growth hormone secretagogue research. It does not describe or endorse any human or veterinary use, dosing or treatment.